Targeted pill for advanced lung cancer with EGFR mutations
Part of Cancer, Lungs & breathing clinical trials.
This study tests an oral pill (BPI-361175) for people with advanced non-small cell lung cancer that has specific EGFR mutations, especially when standard EGFR-targeted treatments are no longer working. The goal is to see if it can shrink tumors or slow growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your lung cancer must be advanced (has spread or cannot be removed by surgery) and have a specific mutation called EGFR.
- You must have already tried standard treatments, including EGFR-targeted pills, and the cancer kept growing.
- For some parts of the study, you need a specific genetic change called C797S in your tumor (detected by a blood or tissue test).
- You must be generally well enough to carry out daily activities on your own (not bedridden).
- Your blood counts, liver, and kidney function must be within certain safe ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
This trial tests a newer type of EGFR targeted therapy pill for people with advanced non-small cell lung cancer who have not had prior treatment and whose cancer has a specific genetic change called a PACC mutation. The goal is to see if the drug works well for this group.
This trial is testing a new targeted pill for people with EGFR-positive non-small cell lung cancer. It's designed for those whose cancer has grown after other treatments, and it works by blocking a specific protein that helps the cancer grow.
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
This trial tests an experimental pill called BEBT-109 for people with a specific type of lung cancer (EGFR exon 20 insertion mutation) that has gotten worse after chemotherapy. The study aims to see if this targeted therapy can shrink tumors or slow cancer growth.
Hear when a new Non-small Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.